Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by AB Science
< Previous
1
2
Next >
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
October 16, 2025
From
AB Science
Via
GlobeNewswire
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
October 14, 2025
From
AB Science
Via
GlobeNewswire
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
October 10, 2025
From
AB Science
Via
GlobeNewswire
AB Science announces a slight delay in the publication of its 2025 half-year financial report
September 30, 2025
From
AB Science
Via
GlobeNewswire
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
July 30, 2025
From
AB Science
Via
GlobeNewswire
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
July 24, 2025
From
AB Science
Via
GlobeNewswire
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
July 04, 2025
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
June 30, 2025
From
AB Science
Via
GlobeNewswire
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
June 23, 2025
From
AB Science
Via
GlobeNewswire
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
June 12, 2025
From
AB Science
Via
GlobeNewswire
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
June 09, 2025
From
AB Science
Via
GlobeNewswire
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
May 19, 2025
From
AB Science
Via
GlobeNewswire
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
May 15, 2025
From
AB Science
Via
GlobeNewswire
AB Science reports its revenues for the year 2024 and provides an update on its activities
May 12, 2025
From
AB Science
Via
GlobeNewswire
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
May 05, 2025
From
AB Science
Via
GlobeNewswire
AB Science will publish its 2024 annual financial report on May 9, 2025
May 01, 2025
From
AB Science
Via
GlobeNewswire
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
April 23, 2025
From
AB Science
Via
GlobeNewswire
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
April 14, 2025
From
AB Science
Via
GlobeNewswire
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
March 04, 2025
From
AB Science
Via
GlobeNewswire
AB Science today provides an update on its masitinib platform
January 29, 2025
From
AB Science
Via
GlobeNewswire
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
January 24, 2025
From
AB Science
Via
GlobeNewswire
AB Science will participate in the Biomed Forum investors conference
January 22, 2025
From
AB Science
Via
GlobeNewswire
AB Science provides a summary of the webcast held on December 16, 2024
December 17, 2024
From
AB Science
Via
GlobeNewswire
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
December 11, 2024
From
AB Science
Via
GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
October 28, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
October 17, 2024
From
AB Science
Via
GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
October 10, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces a slight delay in the publication of its 2024 half-year financial report
September 30, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
September 26, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
September 23, 2024
From
AB Science
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.